

Staphylococcus aureus, Strain P1V44

Catalog No. NR-46063

Product Description:

Staphylococcus aureus (*S. aureus*), strain P1V44 was isolated Belgium in 1999 from a sputum of an 18-year-old female cystic fibrosis patient with a history of methicillin-resistant *S. aureus* (MRSA) colonization and pulmonary exacerbations due to MRSA and *Pseudomonas aeruginosa*. *S. aureus*, strain P1V44 is a borderline MRSA, vancomycin-intermediate *S. aureus* (VISA) strain. *S. aureus*, strain P1V44 was deposited as resistant to amikacin, erythromycin and penicillin. *S. aureus*, strain P1V44 was deposited to BEI Resources as part of the NARSA collection. NR-46063 was produced by inoculation of BEI Resources seed lot 63009595 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% sheep blood in kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

Lot: 70066867

Manufacturing Date: 06MAR2024

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology 1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood Motility (wet mount) Hemolysis 1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood Biochemical characterization Catalase Coagulase ¹ VITEK® 2 Compact (GP card)	Gram-positive cocci Report results Non-motile β-hemolytic Positive Positive <i>S. aureus</i> (≥ 89.9%)	Gram-positive cocci Circular, low convex, entire, smooth and white (Figure 1) Non-motile β-hemolytic Positive Positive <i>S. aureus</i> (95% probability)
Antibiotic Susceptibility Profile² Oxacillin resistance ³ VITEK® (AST-GP78 card) Benzylpenicillin Beta-lactamase Cefoxitin screen Ciprofloxacin Clindamycin Clindamycin (inducible resistance) Erythromycin Linezolid Minocycline Moxifloxacin Nitrofurantoin Oxacillin Rifampicin Tetracycline Tigecycline Trimethoprim/sulfamethoxazole Vancomycin	Resistant Inconclusive Report results Report results Intermediate Report results Inconclusive Resistant Sensitive Sensitive Intermediate Sensitive Inconclusive Resistant Sensitive Sensitive Sensitive Intermediate	Resistant Resistant (0.12 µg/mL) Positive Negative Intermediate (2 µg/mL) Sensitive (≤ 0.12 µg/mL) Negative Resistant (≥ 8 µg/mL) Sensitive (2 µg/mL) Sensitive (≤ 0.5 µg/mL) Intermediate (1 µg/mL) Sensitive (≤ 16 µg/mL) Sensitive (3 µg/mL) Resistant (≥ 32 µg/mL) Sensitive (2 µg/mL) Sensitive (≤ 0.12 µg/mL) ⁴ Sensitive (≤ 10 µg/mL) Intermediate (8 µg/mL)

Certificate of Analysis for NR-46063

TEST	SPECIFICATIONS	RESULTS
Etest® antibiotic test strips 1 day at 35°C in an aerobic atmosphere on Mueller Hinton agar Chloramphenicol Daptomycin Gentamicin Levofloxacin Quinupristin/dalfopristin Teicoplanin	Sensitive Non-susceptible Sensitive Resistant Sensitive Sensitive	Sensitive (6 µg/mL) ⁵ Sensitive (0.75 µg/mL) Sensitive (3 µg/mL) Intermediate (3 µg/mL) ⁶ Sensitive (0.094 µg/mL) Sensitive (2 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1490 base pairs)	≥ 99% sequence identity to <i>S. aureus</i> , strain P1V44 (GenBank: CP123743.1)	100% sequence identity to <i>S. aureus</i> , strain P1V44 (GenBank: CP123743.1)
Purity (post-freeze) 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze) 1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth

¹4 hours at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³1 day at 30°C in an aerobic atmosphere on Mueller Hinton agar containing 6 µg per mL oxacillin and 4% NaCl (Oxacillin Screen agar BBL™ 221952)

⁴MIC Interpretation Guideline: EUCAST Version 4.0 (2014)

⁵*S. aureus*, strain P1V44 was deposited as having an intermediate susceptibility to chloramphenicol. Antibiotic susceptibility testing performed in duplicate determined that strain P1V44 is sensitive to chloramphenicol.

⁶The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

Figure 1: Colony Morphology



/Sonia Bjorum Brower/

Sonia Bjorum Brower

18 SEP 2025

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

